-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RCXmhs/EuPx+JyzCKrWY2F0/gMrRx7FSvoyDnJT3JTqVE7kvW7CIyT+GAFTJkcT2 zh8hf0knfb8fDj20PW/o+g== 0000875320-10-000021.txt : 20100510 0000875320-10-000021.hdr.sgml : 20100510 20100510165115 ACCESSION NUMBER: 0000875320-10-000021 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100507 FILED AS OF DATE: 20100510 DATE AS OF CHANGE: 20100510 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SMITH IAN F CENTRAL INDEX KEY: 0001197032 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 10817026 MAIL ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 4 1 edgar.xml PRIMARY DOCUMENT X0303 4 2010-05-07 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001197032 SMITH IAN F C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE MA 02139 0 1 0 0 EVP & CFO Common Stock 2010-05-07 4 S 0 5869 35.72 D 49008 D Common Stock 2010-05-07 4 S 0 9131 36.16 D 39877 D Common Stock 4401 I 401(k) Transaction made pursuant to Mr. Smith's company approved trading plan established under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $35.72 (range $35.06 to $35.99). Open market sales reported on this line occurred at a weighted average price of $36.16 (range $36.00 to $36.50). Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Kenneth S. Boger, Attorney-In-Fact 2010-05-10 -----END PRIVACY-ENHANCED MESSAGE-----